NEW YORK – SQI Diagnostics and Azova said on Thursday they have signed an agreement for the sale and distribution of an at-home test to detect antibodies against SARS-CoV-2.
Pursuant to Toronto-based SQI receiving Emergency Use Authorization from the US Food and Drug Administration for its COVID-19 Home Antibody Test, Utah-based Azova will sell and distribute the test to its customers in the airline industry, as well as to wholesale clubs, retail pharmacies, grocery chains, US state governments, school districts, universities, and consumers.
Financial and other terms of the deal were not disclosed.
Azova operates a digital health network for COVID-19 testing and vaccination management. SQI said that its test has an accuracy greater than 99 percent, and it detects IgG, IgA, and IgM antibodies against SARS-CoV-2 generated from the nucleocapsid and spike protein regions of the virus.
Under the deal, individuals would receive a collection kit for a blood sample, which will be shipped to an SQI partner CLIA laboratory. Test results will be returned through Azova 12 to 48 hours after the lab receives the specimen.